Skip to content
TrialScanner

NCT06682806

A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

Phase 2TerminatedPRLDLeadMRKCollaborator

Registry record

Lead sponsor
Prelude Therapeutics Incorporated
Conditions
Advanced Solid Tumor; Esophageal Cancer; Metastatic Solid Tumor; Non-small Cell Lung Cancers; SMARCA4 Gene Mutation
Primary completion
Jan 23, 2026Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT06682806 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT06682806: A Study of PRT3789 in... | TrialScanner